How big is Alpha Teknova, Inc.?

As of Jun 18, Alpha Teknova, Inc. has a market capitalization of 288.05 million and reported net sales of 38.25 million with a net profit of -23.29 million over the latest four quarters.

As of Jun 18, Alpha Teknova, Inc. has a market capitalization of 288.05 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 38.25 million, while the sum of Net Profit for the same period is -23.29 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 82.39 million and Total Assets at 118.77 million.

What does Alpha Teknova, Inc. do?

Alpha Teknova, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $10 million and a net loss of $5 million as of March 2025. It has a market cap of $288.05 million, with key metrics indicating no earnings and a negative return on equity.

Overview: <BR>Alpha Teknova, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 10 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 288.05 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.15 <BR>Return on Equity: -29.63% <BR>Price to Book: 3.66<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Alpha Teknova, Inc.?

Is Alpha Teknova, Inc. overvalued or undervalued?

As of August 11, 2021, Alpha Teknova, Inc. is considered overvalued and risky due to high valuation metrics and poor financial performance, with a year-to-date return of -44.43%, significantly underperforming the S&P 500.

As of 11 August 2021, the valuation grade for Alpha Teknova, Inc. moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 4.03 and an EV to Sales ratio of 7.99, both of which suggest a premium valuation relative to its financial performance. Additionally, the negative EV to EBITDA of -18.40 further underscores the challenges the company faces in generating earnings.<BR><BR>In comparison to peers, CytomX Therapeutics, Inc. is categorized as very attractive with a P/E ratio of 7.49, while both Capricor Therapeutics, Inc. and Ocuphire Pharma, Inc. are also deemed risky with P/E ratios of -4.15 and -2.46, respectively. This peer comparison highlights that Alpha Teknova is not only struggling with profitability but is also lagging behind its competitors in terms of valuation metrics. The company's stock has underperformed relative to the S&P 500, with a year-to-date return of -44.43% compared to the index's 12.22%, reinforcing the notion that it may be overvalued in the current market context.

Is Alpha Teknova, Inc. technically bullish or bearish?

As of August 25, 2025, Alpha Teknova, Inc. shows a bearish technical trend with mixed signals from MACD and Bollinger Bands, significantly underperforming the S&P 500 year-to-date with a return of -44.43% compared to the S&P's 12.22%.

As of 25 August 2025, the technical trend for Alpha Teknova, Inc. has changed from mildly bearish to bearish. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals. The Bollinger Bands and KST are both mildly bearish on both weekly and monthly time frames. The moving averages are also mildly bearish on a daily basis, while the Dow Theory shows a mildly bullish stance weekly but bearish monthly. <BR><BR>In terms of performance, Alpha Teknova has underperformed the S&P 500 significantly year-to-date, with a return of -44.43% compared to the S&P's 12.22%, and over the past year, it has returned -7.39% versus the S&P's 17.14%. Overall, the current technical stance is bearish, indicating weakness in the stock's performance.